Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation1
- 27 May 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Transplantation
- Vol. 75 (10) , 1704-1710
- https://doi.org/10.1097/01.tp.0000063937.53702.97
Abstract
To define whether immunosuppressive agents that block the interleukin (IL)-2 pathway could prevent activation-induced cell death of activated T cells in the graft, we measured expression of IL-2, IL-2 receptor alpha chain (CD25), IL-15, Fas, and Fas ligand by real time reverse transcription-polymerase chain reaction in cardiac allografts. We characterized the phenotype of the infiltrating cells (CD3, CD68, CD25) by immunohistochemistry. The proportion of apoptotic graft-infiltrating cells was determined by TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) staining. We analyzed endomyocardial biopsy specimens from cardiac allograft recipients who were treated with anti-CD25 monoclonal antibody (mAb) induction therapy (daclizumab) or with matching placebo in combination with cyclosporine, steroids, and mycophenolate mofetil. Treatment with anti-CD25 mAb affected the number of infiltrating CD3 and CD68 cells and the IL-2-regulated apoptotic pathway. During anti-CD25 mAb treatment, significantly lower intragraft IL-2 and CD25 mRNA transcription levels and decreased numbers of CD25+ T cells were found compared with the levels measured in endomyocardial biopsy specimens from placebo-treated patients (5- to 10-fold, P=0.002 and P<0.0001, respectively). In these samples the intragraft mRNA expression levels of IL-15 were also lower (P=0.02). Inhibition of the IL-2 pathway by anti-CD25 mAb therapy was accompanied by reduced mRNA and protein of Fas ligand and not by reduced Fas expression (P=0.001 and P=0.03). TUNEL staining revealed that the proportion of graft-infiltrating cells was lower in the anti-CD25 mAb patient group than the proportion of apoptotic cells in patients receiving placebo (P=0.06). Our data suggest that immunosuppressive agents that affect the IL-2 pathway hinder the mechanism of activation-induced cell death by which the immune system eliminates alloreactive cells.Keywords
This publication has 21 references indexed in Scilit:
- Conversion from cyclosporin A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-β1 type I receptor expressionClinical Transplantation, 2001
- Prevention of Rejection in Cardiac Transplantation by Blockade of the Interleukin-2 Receptor with a Monoclonal AntibodyNew England Journal of Medicine, 2000
- MATURE T LYMPHOCYTE APOPTOSIS—Immune Regulation in a Dynamic and Unpredictable Antigenic EnvironmentAnnual Review of Immunology, 1999
- ANTI-CD25 THERAPY REVEALS THE REDUNDANCY OF THE INTRAGRAFT CYTOKINE NETWORK AFTER CLINICAL HEART TRANSPLANTATION1Transplantation, 1999
- Intragraft cytokine gene expression: implications for clinical transplantationTransplant International, 1998
- BLOCKADE OF THE INTERLEUKIN (IL)-2/IL-2 RECEPTOR PATHWAY WITH A MONOCLONAL ANTI-IL-2 RECEPTOR ANTIBODY (BT563) DOES NOT PREVENT THE DEVELOPMENT OF ACUTE HEART ALLOGRAFT REJECTION IN HUMANSTransplantation, 1998
- Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal TransplantationNew England Journal of Medicine, 1998
- MANIPULATION OF CYTOKINE NETWORKS IN TRANSPLANTATIONTransplantation, 1997
- Normal clonal expansion but impaired Fasmediated cell death and anergy induction in interleukin‐2‐deficient miceEuropean Journal of Immunology, 1995
- lnterleukin-2 programs mouse αβ T lymphocytes for apoptosisNature, 1991